奥拉帕利维持治疗对铂敏感复发卵巢癌患者健康相关生活质量及以患者为中心结局的影响
SOLO2/ENGOT Ov-21三期试验纳入196例奥拉帕利和99例安慰剂患者,评估gBRCA1/2突变铂敏感复发卵巢癌化疗后维持治疗的生活质量。奥拉帕利组QAPFS和TWiST均显著延长。
要点
- 奥拉帕利维持治疗未对健康相关生活质量产生显著不利影响。
- 奥拉帕利组质量调整无进展生存期和无需毒性症状生存时间均显著优于安慰剂。
- 以患者为中心的结局支持奥拉帕利带来的无进展生存期获益。
核心结论
- 奥拉帕利维持治疗对比安慰剂未对HRQOL产生显著不利影响,且在TWiST和QAPFS上具有临床意义的以患者为中心获益。
研究设计与样本
- SOLO2/ENGOT Ov-21为安慰剂对照三期随机试验,196例随机分配至奥拉帕利片剂300mg每日两次,99例至安慰剂。
- 随机分层因素为对既往化疗的反应(完全缓解 vs 部分缓解)和无铂间期长度(>6-12个月 vs >12个月)。
- 预设主要HRQOL分析评估研究前12个月TOI评分相对基线的变化,需基线及至少一次可评估随访表方可纳入分析。
临床怎么用
- 对于gBRCA1/2突变铂敏感复发卵巢癌化疗后患者,奥拉帕利维持治疗在不损害HRQOL的前提下延长QAPFS和TWiST,支持其用于维持治疗。
- 以患者为中心的终点(TWiST和QAPFS)可作为未来维持治疗试验的评估指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the phase 3 SOLO2 trial (ENGOT Ov-21), maintenance therapy with olaparib tablets significantly prolonged progression-free survival (primary endpoint) compared with placebo in patients with a germline BRCA1 or BRCA2 (BRCA1/2) mutation and platinum-sensitive, relapsed ovarian cancer who had received two or more lines of previous chemotherapy. The most common subjective adverse effects included fatigue, nausea, and vomiting, which were typically low grade and self-limiting. Our a-priori hypothesis was that maintenance olaparib would not negatively affect health-related quality of life (HRQOL) and additionally that the prolongation of progression-free survival with olaparib would be underpinned by additional patient-centred benefits. METHODS: In SOLO2, 196 patients were randomly assigned to olaparib tablets (300 mg twice daily) and 99 to placebo. Randomisation was stratified by response to previous chemotherapy (complete vs partial) and length of platinum-free interval (>6-12 vs >12 months). The prespecified primary HRQOL analysis evaluated the change from baseline in the Trial Outcome Index (TOI) score during the first 12 months of the study. To be assessable, patients had to have an evaluable score at baseline and at least one evaluable follow-up form. Secondary planned quality-of-life (QOL) analyses included the duration of good quality of life (defined as time without significant symptoms of toxicity [TWiST] and quality-adjusted progression-free survival [QAPFS]). Efficacy and QOL outcomes were analysed in all randomly assigned patients (the full analysis set), and safety outcomes were analysed in all randomly assigned patients who received at least one dose of study drug. This ongoing study is registered with ClinicalTrials.gov, number NCT01874353, and is closed to new participants. FINDINGS: The adjusted average mean change from baseline over the first 12 months in TOI was -2·90 (95% CI -4·13 to -1·67) with olaparib and -2·87 (-4·64 to -1·10) with placebo (estimated difference -0·03; 95% CI -2·19 to 2·13; p=0·98). Mean QAPFS (13·96 [SD 10·96] vs 7·28 [5·22] months; difference 6·68, 95% CI 4·98-8·54) and mean duration of TWiST (15·03 [SD 12·79] vs 7·70 [6·42] months; difference 7·33, 95% CI 4·70-8·96) were significantly longer with olaparib than with placebo. INTERPRETATION: Olaparib maintenance therapy did not have a significant detrimental effect on HRQOL compared with placebo. There were clinically meaningful patient-centred benefits in both TWiST and QAPFS despite the adverse effects associated with olaparib. These patient-centred endpoints support the improvement in progression-free survival, the primary endpoint in SOLO2, and should be included in future trials of maintenance therapies. FUNDING: AstraZeneca.
引用
- Friedlander M, Gebski V, Gibbs E, et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol. 2018. PMID: 30026002. doi:10.1016/S1470-2045(18)30343-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。